Arizona Tribune - Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose’s Potential in Chip Manufacturing and More

SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 13, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting Ainos' strategic collaboration with Advanced Semiconductor Engineering, Inc. ("ASE"), the world's largest provider of semiconductor packaging and testing services. The partnership will integrate Ainos' AI Nose, an AI-powered electric nose technology, into ASE's factories, expanding AI Nose's opportunity in semiconductor manufacturing. The report also highlights AI Nose's role in predictive maintenance, environmental monitoring, and process optimization in next-generation semiconductor production.

Key Highlights from the Report:

• Another Key Win in Expanding AI Nose's Industrial Opportunities: This collaboration with ASE further validates AI Nose's industrial applications, building on Ainos' prior milestone in Japanese semiconductor factories, where AI Nose hit nearly 80% accuracy in detecting 22 VOCs. Moreover, Ainos last week formed a partnership with Japan's service robot developer, ugo, Inc., to integrate AI Nose into ugo's products, enabling the first robots with the sense of smell.

• Unlocking Scent's Potential in Chip Manufacturing: Semiconductor factories involve chemical intensive processes, providing an excellent use-case for AI Nose. For a long time, invisible air-borne chemical's impact on chip manufacturing has been under-discovered. By digitizing scent into Smell ID, AI Nose can unlock scent's hidden power in semiconductor manufacturing, elevating predictive maintenance, precision control, yield optimization, and energy efficiency.

• AI Nose Aligns with ASE's AI-Driven Manufacturing Strategy: ASE is the world's largest outsourced semiconductor assembly and test (OSAT) provider, operating under ASE Technology Holding Co. Ltd. (TAIEX: 3711, NYSE: ASX), which is approximately a $21 billion market-cap company with $19 billion in FY24 revenue. ASE has been accelerating smart manufacturing, operating 46 lights-out factories and employing over 700 automation engineers.

• Partnership to Integrate AI Nose in ASE Facilities and Beyond: Ainos and ASE will first optimize AI Nose for semiconductor packaging and testing settings. Next, they will plan large-scale deployment within ASE and explore broader industrial applications, paving the way for new revenue streams for Ainos.

Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_03112025

About Ainos, Inc.

Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify Ainos' commitment to enabling AI with the ability to smell and individuals to live healthier. Ainos' clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. For more information, visit: www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact Information
Feifei Shen
[email protected]

SOURCE: Ainos, Inc.

View the original press release on ACCESS Newswire

O.Ortiz--AT